Barclays
JANX icon

Barclays’s Janux Therapeutics JANX Stock Holding History

Barclays’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$978K Buy
63,679
+7,691
+14% +$111K ﹤0.01% 2804
2026
Q1 		$778K Sell
55,988
-165,245
-75% -$2.27M ﹤0.01% 2903
2025
Q4 		$3.05M Buy
221,233
+77,209
+54% +$1.82M ﹤0.01% 2624
2025
Q3 		$3.52M Buy
144,024
+11,683
+9% +$285K ﹤0.01% 2459
2025
Q2 		$3.06M Buy
132,341
+64,575
+95% +$1.7M ﹤0.01% 2525
2025
Q1 		$1.83M Sell
67,766
-196,204
-74% -$7.4M ﹤0.01% 2694
2024
Q4 		$14.1M Buy
263,970
+89,909
+52% +$4.76M ﹤0.01% 1314
2024
Q3 		$7.91M Buy
174,061
+144,883
+497% +$6.3M ﹤0.01% 1659
2024
Q2 		$1.22M Buy
29,178
+13,678
+88% +$642K ﹤0.01% 2481
2024
Q1 		$584K Sell
15,500
-32,222
-68% -$702K ﹤0.01% 3492
2023
Q4 		$512K Buy
47,722
+29,800
+166% +$258K ﹤0.01% 3854
2023
Q3 		$181K Buy
17,922
+12,443
+227% +$143K ﹤0.01% 3346
2023
Q2 		$65K Sell
5,479
-3,425
-38% -$45.8K ﹤0.01% 3724
2023
Q1 		$108K Buy
8,904
+4,296
+93% +$71.5K ﹤0.01% 4135
2022
Q4 		$60.7K Buy
4,608
+3,880
+533% +$56.8K ﹤0.01% 4471
2022
Q3 		$10K Sell
728
-132
-15% -$1.76K ﹤0.01% 4301
2022
Q2 		$11K Sell
860
-2,088
-71% -$24.7K ﹤0.01% 4599
2022
Q1 		$42K Buy
+2,948
New +$48.2K ﹤0.01% 4180

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Barclays's JANX Position: Q2 2026 in Review

Barclays increased its Janux Therapeutics (JANX) stake by 14% in Q2 2026, buying an estimated $111K and bringing the position to 63,679 shares worth $978K. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Barclays first reported a position in JANX in Q1 2022 and has held it in 18 quarters since. The position peaked at $14.1M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Barclays held 63,679 shares of Janux Therapeutics worth $978K as of Q2 2026.
  • Barclays bought 7,691 Janux Therapeutics shares in Q2 2026, an estimated $111K.
  • Janux Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2804 holding.
  • Barclays first reported a position in Janux Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Janux Therapeutics position peaked at $14.1M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.